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Objectives: Accumulating evidence implicates altered DNA methylation in psychiatric 
disorders, including bipolar disorder (BD) and major depressive disorder (MDD). It is 
not clear, however, whether these changes are causative or result from illness pro-
gression or treatment. To disentangle these possibilities we profiled genome- wide 
DNA methylation in well, unrelated individuals at high familial risk of mood disorder. 
DNA methylation was compared between individuals who subsequently developed 
BD or MDD [ill later (IL)] and those who remained well [well later (WL)].
Methods: DNA methylation profiles were obtained from whole- blood samples from 
22 IL and 23 WL individuals using the Infinium HumanMethylation450 BeadChip. Dif-
ferential methylation was assessed on a single- locus and regional basis. Pathway 
analysis was performed to assess enrichment for particular biological processes 
amongst nominally significantly differentially methylated loci.
Results: Although no locus withstood correction for multiple testing, uncorrected P- 
values provided suggestive evidence for altered methylation at sites within genes pre-
viously implicated in neuropsychiatric conditions, such as Transcription Factor 4 (TCF4) 
and Interleukin 1 Receptor Accessory Protein-Like 1 ([IL1RAPL1]; P≤3.11×10−5). Pathway 
analysis revealed significant enrichment for several neurologically relevant pathways 
and functions, including Nervous System Development and Function and Behavior; these 
findings withstood multiple testing correction (q≤0.05). Analysis of differentially meth-
ylated regions identified several within the major histocompatibility complex (P≤.000 
479), a region previously implicated in schizophrenia and BD.
Conclusions: Our data provide provisional evidence for the involvement of altered whole- 
blood DNA methylation in neurologically relevant genes in the aetiology of mood disorders. 
These findings are convergent with the findings of genome- wide association studies.
K E Y W O R D S
450K array, bipolar disorder, DNA methylation, Interleukin 1 Receptor Accessory Protein-Like 1, 
major depressive disorder, premorbid, Transcription Factor 4
1Medical Genetics Section, Centre 
for Genomic and Experimental 
Medicine, Institute of Genetics and 
Molecular Medicine, The University of 
Edinburgh, Western General Hospital, 
Edinburgh, UK
2Division of Psychiatry, The University 
of Edinburgh, Royal Edinburgh 
Hospital, University of Edinburgh, 
Edinburgh, UK
3Centre for Cognitive Ageing and Cognitive 
Epidemiology, The University of Edinburgh, 
Edinburgh, UK
Correspondence
Kathryn Louise Evans, Medical Genetics 
Section, Centre for Genomic and 
Experimental Medicine, Institute of Genetics 
and Molecular Medicine, The University 
of Edinburgh, Western General Hospital, 
Edinburgh, UK.
Email: kathy.evans@igmm.ed.ac.uk
O R I G I N A L  A R T I C L E
Preliminary assessment of pre- morbid DNA methylation in 
individuals at high genetic risk of mood disorders
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Niamh Margaret Ryan1 | David John Porteous1,3 | Andrew Mark McIntosh2,3 |  
Kathryn Louise Evans1,3
Mood disorders, comprising bipolar disorder (BD) and major depres-
sive disorder (MDD), represent a leading cause of disability, causing 
considerable suffering and decreased productivity. Both conditions 
are heritable1,2 and genetic risk factors for the two conditions over-
lap.3 First- degree relatives of individuals diagnosed with BD are at an 
increased risk of developing both BD (relative risk=5.8–7.9) and MDD 
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(relative risk=2.1).1 Whilst there is a clear genetic component to BD 
and MDD, environmental risk factors also play an important role, as 
revealed by imperfect monozygotic twin concordance.4–6
DNA methylation, the addition of a methyl group to the fifth carbon 
atom of cytosine, normally in the context of a CpG dinucleotide, can play 
a role in transcriptional regulation.7 Altered gene expression has been 
widely reported in patients with mood disorders8–10 and recent studies 
support the existence of DNA methylation changes in individuals with 
these conditions,11–15 implying a potential mechanistic link. Importantly, 
DNA methylation is under the control of both genetic and environmental 
factors,16,17 rendering it a plausible candidate mechanism for mediating 
the deleterious effects of experiences such as obstetric complications, 
antenatal maternal virus and childhood neglect, which are known to 
increase risk for mood disorders.18–20 Consistent with this possibility, 
differences in DNA methylation have been observed in monozygotic 
twins who are discordant for BD11 or MDD.12,13
The evidence for altered DNA methylation in individuals with 
mood disorders comes from the study of individuals who are ill and, 
usually, medicated. It is, therefore, impossible to determine whether 
observed methylation differences play a primary role in development 
of mood disorders or reflect the effects of illness progression and/
or treatment. The likely confounding effect of medication has been 
demonstrated by recent studies showing the modulation of DNA 
methylation by antidepressants and mood stabilizers.21–23 Another 
important limitation when considering the evidence for altered DNA 
methylation in mood disorders is that the majority of studies have 
profiled DNA from peripheral tissues, such as blood. This reflects the 
practical difficulties of obtaining DNA from the more aetiologically 
relevant brain. Within- individual correlation between blood and brain 
methylation levels has been shown to be limited for the majority of 
sites, although there are some exceptions.24 This observation does 
not, however, detract from the potential utility of blood- based meth-
ylation signatures as a biomarker for mood disorders. Moreover, it is 
possible that, when considered at a pathway level, differences in DNA 
methylation in the blood might indicate the types of biological pro-
cesses perturbed in mood disorders.
Here, we sought to circumvent some of these potential confounds 
by profiling whole- blood genome- wide DNA methylation in the unaf-
fected first- or second- degree relatives of individuals with BD, who are 
at increased risk of developing mood disorders themselves (henceforth 
referred to as high- risk individuals). These individuals were recruited 
as part of the Edinburgh- based Scottish Bipolar Family Study (BFS). 
Studies of this cohort have identified a number of differences in brain 
structure, function and connectivity in individuals at high risk of devel-
oping mood disorders.25,26 Moreover, in a recent functional magnetic 
resonance imaging study, increased insula activation during a sentence 
completion task was found to be predictive of future illness in well 
high- risk individuals.27 In addition, we have recently shown altered 
miRNA expression in high- risk individuals,28 thus highlighting altered 
regulation of gene expression as a putative risk mechanism. Blood 
samples for DNA methylation profiling were obtained upon recruit-
ment to the cohort and the diagnostic status of participants evaluat-
ed biennially, permitting baseline DNA methylation to be compared 
between unaffected individuals who later developed a mood disorder 
(ill later [IL]) and those who remained well (well later [WL]).
1  | PATIENTS AND MATERIALS
1.1 | Sample
Genome- wide DNA methylation was profiled in whole- blood sam-
ples obtained from 49 individuals at higher genetic risk of developing 
a mood disorder, all of whom were unaffected at the time of blood 
draw. These individuals were recruited as part of the Scottish Bipolar 
Family Study (BFS), as described previously.25,26 Briefly, at the time 
of recruitment, high- risk individuals met the following selection cri-
teria: (i) at least one first- degree or two second- degree relatives with 
bipolar I disorder, (ii) no personal history of BD, and (iii) aged 16–25 y. 
Exclusion criteria were: a history of major depression, mania, hypo-
mania, psychosis, generalized anxiety disorder, panic disorder, eating 
disorder, or substance dependence; an IQ<70 or clinical diagnosis of 
learning disability; any major neurological disorder or history of head 
injury that included loss of consciousness; and any contraindications 
to magnetic resonance imaging (MRI). Only unrelated individuals were 
included. All participants provided written informed consent and the 
study was approved by the Multicentre Research Ethics Committee for 
Scotland and performed in accordance with the Helsinki Declaration 
of 1975.
1.2 | Clinical assessments
Baseline clinical assessments were carried out at the time of each par-
ticipant’s blood draw. All individuals were well at the time of recruit-
ment. Follow- up assessments have been performed at approximately 
2- y intervals since the baseline assessment. Clinical interviews were 
conducted by two psychiatrists. At baseline, current depressive and 
manic symptoms were assessed using the Hamilton Depression Rating 
Scale (HDRS)29 and the Young Mania Rating Scale (YMRS),30 respec-
tively. At follow- up interviews, participants were reassessed using 
the Structured Interview for DSM- IV to determine whether they had 
developed a mood disorder (MDD or BD). When participants were 
unable to attend follow- up assessments, diagnosis was made on the 
basis of information regarding current clinical care, obtained through 
contact with the National Health Service (n=8; of whom two were 
diagnosed with a mood disorder and six remained well). On the basis of 
their diagnosis at follow- up assessments, the high- risk individuals were 
split into two groups: a group who remained well at every subsequent 
follow- up assessment (WL) and a group who had developed a mood 
disorder (IL). Statistical differences in HDRS and YMRS scores were 
assessed by Kruskal- Wallis tests. Statistical differences in the length of 
follow- up time (defined as the number of years between the baseline 
assessment and either [i] the assessment where a participant was diag-
nosed with either MDD or BD for the IL group or [ii] the most recent 
follow- up assessment for the WL group) were assessed by one- tailed 
t test to determine whether the IL group had been followed up for 
longer than the WL group. Statistical significance was defined as P≤.05.
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1.3 | Extraction of blood DNA
Blood (9 mL) was collected in an EDTA tube. DNA was extracted at the 
Wellcome Trust Clinical Research Facility (WTCRF) at the University 
of Edinburgh, using the Nucleon BACC2 Genomic DNA Extraction Kit 
(Fisher Scientific, Loughborough, UK), following the manufacturer’s 
instructions.
1.4 | Genome- wide methylation profiling
Whole- blood genomic DNA (500 ng) was treated with sodium bisul-
phite using the EZ- 96 DNA Methylation Kit (Zymo Research, Irvine, 
CA), following the manufacturer’s instructions. DNA methylation 
was assessed using the Infinium HumanMethylation450 BeadChip 
(Illumina Inc., San Diego, CA), according to the manufacturer’s proto-
col. Samples were assigned to chips such that, as far as possible, group 
and gender were counterbalanced across chips.
Raw intensity (.idat) files were read into R using the minfi pack-
age,31 which was used to perform initial quality control assess-
ments. Subsequently, filtering of poor- performing samples and sites 
was performed. Samples were removed from the dataset if: (i) they 
failed any of the quality control assessments carried out in minfi; or 
(ii) ≥1% sites had a detection P- value of >.05. Probes were removed 
from the dataset if: (i) the CpG site (and/or the base before the 
CpG site, for Type I probes) overlapped a single nucleotide polymor-
phism (SNP) with a minor allele frequency of ≥5% in the European 
population from the 1000 Genomes Project32,33; (ii) they were pre-
dicted to cross- hybridize33; (iii) they had more than five samples 
with a beadcount of <3; or (iv) ≥0.5% samples had a detection P- 
value of >.05.
The data were normalized using the dasen method from the R 
package wateRmelon.34 This involves adjusting the background differ-
ence between Type I and Type II assays (by adding the offset between 
Type I and II probe intensities to Type I intensities). Between- array 
quantile normalization is then performed for the methylated and 
unmethylated signal intensities separately (Type I and Type II assays 
normalized separately).
Prior to downstream analyses, M-values, defined as 
M=log2([M+100]/[U+100]), where M represents the methylated sig-
nal intensity and U represents the unmethylated signal intensity, were 
calculated for the normalized data.
1.5 | Assessment of between- group differences in 
whole- blood cellular composition
In order to assess between- group differences in cellular composition, 
estimated cell counts for B- lymphocytes, granulocytes, monocytes, 
natural killer cells, CD4+ T- lymphocytes and CD8+ T- lymphocytes 
were generated using the estimateCellCounts() function in minfi. 
This function implements Jaffe and Irizarry’s35 modified version of 
Houseman’s36 algorithm. Between- group differences in cell compo-
sition were assessed using a Student’s t test. A P-value of ≤.05 was 
deemed to represent a significant between- group difference.
1.6 | Surrogate variable analysis
DNA methylation can be influenced by many sources of variation, 
making it important to account for these variables when assessing dif-
ferential methylation. A complicating factor is that many sources of 
variation are unknown or unmeasured. Even when potential sources of 
variation are measured, it is not always clear how best to model these 
potential confounding variables.37 Surrogate variable analysis (SVA) 
identifies a set of significant surrogate variables (SVs), the linear com-
bination of which represents variation in DNA methylation that is not 
attributable to the primary variable(s) of interest. When fitted as covar-
iates in the linear models implemented to identify differentially meth-
ylated positions (DMPs), the SVs control for sources of unmeasured/
unmodelled variation (e.g. cell composition and smoking status), which 
might otherwise confound the relationship between DNA methylation 
and the independent variable of interest.37,38 An advantage of SVA 
is that it allows for complex relationships between confounders and 
DNA methylation, for example interactions between confounding var-
iables. SVA was carried out using the “be” method with the R package 
SVA,39 fitting group (IL or WL) as the primary variable of interest and 
age and gender as adjustment variables. It should be noted that no dis-
tinction was made between IL individuals who later developed MDD 
and those who developed BD when estimating surrogate variables.
1.7 | Identification of differentially 
methylated positions
DMPs were identified using the R package limma40 by fitting linear 
models with the outcome variable “M- value” and the predictor vari-
ables “group” (IL or WL), “gender,” and “age” together with the sig-
nificant SVs. Correction for multiple testing was implemented using 
the Benjamini- Hochberg false discovery rate (FDR), with q- values of 
≤0.05 deemed to be significant.
1.8 | Assessment of the correlation between 
blood and brain methylation
For loci of interest, an indicator of the likely correlation between blood 
and brain methylation was obtained using the recently developed 
Blood Brain DNA Methylation Comparison Tool (http://epigenetics.
iop.kcl.ac.uk/bloodbrain/24). This tool permits the user to investigate 
the correlation between DNA methylation in the blood and in four dif-
ferent brain regions (entorhinal cortex [ERC], prefrontal cortex [PFC], 
superior temporal gyrus [STG] and cerebellum [CBM]), using matched 
samples obtained from 71–75 individuals who were assessed using 
the Infinium HumanMethylation450 BeadChip. Pearson’s correlation 
coefficients obtaining a P- value ≤.05 were considered statistically 
significant.
1.9 | Pathway analysis
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood City, 
CA; www.ingenuity.com) was used to identify canonical pathways 
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(defined as manually curated, well- characterized metabolic and cell 
signalling pathways), diseases and biological functions that were 
enriched amongst the genes containing methylation sites that attained 
an uncorrected P- value of ≤.01 (n=3272). IPA assesses enrichment 
using the right- tailed Fisher’s exact test. As multiple hypotheses were 
tested, the Benjamini- Hochberg FDR method was implemented to 
calculate q- values. We defined statistical significance as q≤0.05. The 
list of genes targeted by probes that were included in the DMP analy-
sis was used as the reference set (n=22 255).
1.10 | Identification of differentially 
methylated regions
Differentially methylated regions (DMRs) were identified using a 
modified version of the champ.lasso function implemented in the R 
package ChAMP.41,42 DMRs were defined as regions containing three 
or more adjacent probes within a defined lasso region showing uni-
directional changes in methylation that attained nominal significance 
(P≤.05) in the DMP analysis. The lasso region was set to 2 kb and 
was scaled according to the local genomic/epigenomic landscape.41 
According to champ.lasso’s default settings, DMRs were merged with 
neighbouring DMRs where they were separated by less than 1 kb. 
P- values were estimated for each DMR according to the method 
described by Butcher et al.41. Briefly, individual probe P- values were 
combined using Stouffer’s method, weighting each probe P- value by 
the underlying correlation structure of the M- values. P- values from 
correlated probes were down- weighted whilst P- values from uncorre-
lated probes were up-weighted. A DMR P- value meeting a Benjamini- 
Hochberg FDR- corrected threshold of ≤.05 was required for a DMR 
to be included in the final DMR lists.
2  | RESULTS
2.1 | Quality control and data filtering
In order to mitigate potential confounds, 7219 probes affected 
by SNPs and 30 165 probes predicted to cross- hybridize33 were 
removed from the dataset. The overall success of DNA methylation 
profiling was then assessed using the internal quality control probes. 
This revealed incomplete bisulphite conversion in two samples, which 
were omitted from downstream analyses. Finally, 11 182 probes were 
removed as they had either (i) more than five samples with a bead-
count <3 or (ii) ≥0.5% samples with a detection P- value of >.05. Two 
samples were excluded as >1% sites had a detection P- value >.05. 
At the end of this filtering process, the dataset comprised 437 239 
probes measured in 23 individuals who remained well (WL) and 22 
individuals who later developed a mood disorder (IL).
2.2 | Sample demographics
Genome- wide DNA methylation was profiled using the Infinium 
HumanMethylation450 BeadChip in whole- blood samples from indi-
viduals at high familial risk of developing a mood disorder who were 
well at the time of blood sampling. Of the 45 well high- risk individuals 
successfully profiled in this study, 22 have subsequently developed 
either MDD or BD (MDD=19; BD=3) and 23 have remained well. 
These two groups are referred to as “ill later” (IL) and “well later” (WL), 
respectively. Sample demographic information is presented in Table 1, 
with further diagnostic information available in Table S1. There were 
no significant differences between the groups in terms of gender, age, 
cigarette smoking, or depressive or manic symptoms. Importantly, 
the IL group had not been followed up for longer than the WL group 
(mean follow- up years: WL=4.67, IL=2.68, t=−4.41, P>.99).
2.3 | Assessment of between- group differences in 
cell composition
As whole blood is composed of multiple different cell types, each 
characterized by a specific DNA methylation profile, variation in the 
cellular composition of blood samples can confound epigenome- wide 
association studies.35 We therefore carried out a between- group 
comparison of the estimated proportions of six blood cell subtypes. A 
significant between- group difference was identified in one cell type, 
CD4+ T- cell proportions (t=2.87; P=.006 35; for complete results see 
Table S2). In the presence of low levels of cellular heterogeneity, SVA 
can be used to empirically control for cell type composition.35
2.4 | Surrogate variable analysis
In order to control for the potentially confounding effects of unmeas-
ured or unmodelled variables, SVs were estimated using the R pack-
age SVA.39 SVA identified 11 significant SVs. The linear combination 
of these SVs represents the combined effects of any confounding 
TABLE  1 Sample demographic information
Variables WL (n=23) IL (n=22)
Test 
statistic
P- 
value
Gender, % male 56.5 45.5 NAe .556
Age, ya 21.7 (2.77) 21.4 (3.22) t=−.344 .732
HDRS scoreb 0 (0–1.75) 0 (0–9) W=115 .176
YMRS scoreb 0 (0–0) 0 (0–0) W=99 .502
Smoker, % yesc,d 27.3 50.0 NAe .215
If yes, cigarettes/
dayb
11 (4.75–14) 6 (2–15) W=22.5 .313
Follow- up time, ya,f 4.67 (1.76) 2.68 (1.18) t=−4.41 >.990
HDRS, Hamilton Depression Rating Scale; IL, ill later (well high- risk indi-
viduals who developed a mood disorder); NA, not applicable; WL, well later 
(well high- risk individuals who remained well); YMRS, Young Mania Rating 
Scale.
aGroup means and standard deviations for normally distributed variables.
bGroup medians and interquartile ranges for non- normally distributed 
variables.
cPercentage “yes” for categorical variables.
dSmoking data were not available for one WL participant.
eFisher’s exact test.
fOne- tailed t test.
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variables that exert a systematic effect on DNA methylation, such as 
variation in cellular composition.
2.5 | Assessment of differential methylation
Differential methylation was assessed at 437 239 sites that survived 
quality control filtering. The presence of DMPs was assessed by linear 
models that included the predictor variables group (IL or WL), age, 
gender and 11 significant surrogate variables. Inspection of a quantile- 
quantile plot of observed vs expected P- values did not indicate any 
systematic bias in the data (Fig. S1), consistent with the genomic infla-
tion factor of 1.01. The 20 most significantly differentially methylated 
loci identified in the IL group compared to the WL group are shown in 
Table 2 (see Table S3 for the top 100 loci; see Fig. S2 for plots of the 
top 10 loci). No locus remained significant after correction for multiple 
testing; however, it was of interest that loci mapping to genes previ-
ously implicated in neuropsychiatric conditions were amongst those 
loci with the most significant unadjusted P- values. These genes includ-
ed Transcription Factor 4 (TCF4) (P=3.11×10−5), variation in which has 
been associated with schizophrenia in genome- wide association anal-
ysis,43 and Interleukin 1 Receptor Accessory Protein-Like 1 (IL1RAPL1) 
(P=1.77×10−5), disruption/deletion of which has been identified in 
individuals with mental retardation and/or autism spectrum disorder 
(ASD).44–50 No relationship was found between methylation and esti-
mated CD4+ T- cell proportion at either the TCF4 site or the IL1RAPL1 
site (TCF4: t=−1.22, P=.230; IL1RAPL1: t=1.38, P=.176).
As DNA methylation was assessed in the blood rather than in the 
brain, it was important to establish whether the nominally significant 
differences in methylation we observed in the blood might indicate 
the presence of methylation differences in the brain. By assessing 
DNA methylation in matched blood and brain samples from 71–75 
individuals, Hannon et al.24 have generated an online database (http://
epigenetics.iop.kcl.ac.uk/bloodbrain/) of coefficients for the correla-
tion between DNA methylation in the blood and four different brain 
regions (PFC, ERC, STG, and CBM). Blood−brain correlation coef-
ficients for each of the 20 most significantly differentially methyl-
ated loci are presented in Table S4. Ten of these loci were found to 
show a significant correlation between methylation in the blood and 
TABLE  2 The top 20 differentially methylated positions identified in the well high- risk individuals who developed a mood disorder (ill later 
[IL]) compared to the well high- risk individuals who remained well (well later [WL]), ranked by uncorrected P- value
Probe ID Gene symbol Chr. Coordinatea P- value WL β (mean) IL β (mean) β differenceb
cg07398767 CA10 17 50237205 3.72×10−6 0.384 0.332 −0.053
cg08292919 GABBR1 6 29565696 4.22×10−6 0.900 0.880 −0.020
cg18995182 COL4A5; COL4A6 X 107682860 4.62×10−6 0.386 0.350 −0.036
cg19006127 — 4 3794737 5.97×10−6 0.205 0.187 −0.018
cg08608800 ZC3H13 13 46626937 6.91×10−6 0.159 0.138 −0.021
cg19199483 — 13 111483035 1.26×10−5 0.960 0.954 −0.007
cg01642827 GET4 7 925664 1.30×10−5 0.919 0.910 −0.009
cg03773183 — 17 79325994 1.33×10−5 0.781 0.854 0.074
cg01724150 NMNAT3 3 139397363 1.64×10−5 0.413 0.347 −0.066
cg26893134 FRK 6 116381904 1.73×10−5 0.914 0.893 −0.021
cg06927864 IL1RAPL1 X 28604661 1.77×10−5 0.278 0.343 0.065
cg19298821 C5orf48 5 125967357 2.00×10−5 0.918 0.932 0.013
cg00662273 PDPK1 16 2648122 2.03×10−5 0.932 0.921 −0.011
cg10827045 PPT1 1 40562842 2.09×10−5 0.092 0.101 0.009
cg06352873 DCBLD2 3 98596709 2.33×10−5 0.841 0.821 −0.020
cg08883995 MGMT 10 131389152 2.37×10−5 0.911 0.923 0.012
cg24507551 GTF2H4 6 30877958 2.67×10−5 0.896 0.908 0.011
cg08187750 PIWIL1 12 130824529 2.68×10−5 0.674 0.620 −0.055
cg02328223 MGLL 3 127541927 3.08×10−5 0.097 0.110 0.013
cg15171911 TCF4 18 53068921 3.11×10−5 0.713 0.671 −0.042
aGRCh37/hg19.
bIL β mean–WL β mean.
CA10: Carbonic Anhydrase 10; GABBR1: Gamma-Aminobutyric Acid Type B Receptor Subunit 1; COL4A5: Collagen Type IV Alpha 5; COL4A6: Collagen 
Type IV Alpha 6; ZC3H13: Zinc finger CCCH domain-containing protein 13; GET4: Golgi To ER Traffic Protein 4; NMNAT3: Nicotinamide Nucleotide 
Adenylyltransferase 3; FRK: Fyn Related Src Family Tyrosine Kinase; IL1RAPL1: Interleukin 1 Receptor Accessory Protein Like 1; C5orf48: Chromosome 5 
Open Reading Frame 48; PDPK1: 3-Phosphoinositide Dependent Protein Kinase 1; PPT1: Palmitoyl-Protein Thioesterase 1; DCBLD2: Discoidin, CUB And 
LCCL Domain Containing 2; MGMT: O-6-Methylguanine-DNA Methyltransferase; GTF2H4: General Transcription Factor IIH Subunit 4; PIWIL1: Piwi Like 
RNA-Mediated Gene Silencing 1; MGLL: Monoglyceride Lipase; TCF4: Transcription Factor 4.
6  |  
  
 Walker et al.
methylation in at least one brain region. Using the criteria defined 
by Hannon et al.,24 whole- blood methylation at one of these ten loci 
showed strong correlation (explaining at least 50% of the variance) and 
methylation levels at an additional three loci showed moderate cor-
relation (explaining at least 20% of the variance) with methylation in at 
least one brain region.
Of particular note, methylation at the locus mapping to IL1RAPL1 
is significantly correlated between the blood and all four brain 
regions (P- value and correlation range: P=1.02×10−8; r2=.381 [ERC]–
P=5.7×10−6; r2=.259 [CBM]). Three other loci (mapping to Carbonic 
Anhydrase-Related Protein 10 [CA10], Collagen Type IV, Alpha 5/6 
[COL4A5/COL4A6], and an intergenic region on chromosome 17) show 
significant correlation between the blood and all four brain regions, 
with the correlations involving the loci mapping to COL4A5/COL4A6 
and the intergenic region showing moderate and strong correlations 
with brain methylation, respectively. An additional locus, mapping to 
Piwi-Like RNA-Mediated Gene Silencing 1 (PIWIL1), is significantly cor-
related between the blood and the three cortical regions, explaining 
a moderate proportion of the variance in methylation in each brain 
region.
In order to ascertain whether genes involved in particular bio-
logical pathways and functions were over- represented amongst 
those harbouring loci showing the most significant differences in 
methylation, pathway analysis was performed. This resulted in the 
identification of several pathways and functions pertinent to nervous 
system function and current hypotheses regarding the pathogenesis 
of mood disorders (Table 3). These included the canonical pathways 
“Dopamine- DARPP32 Feedback in cAMP Signalling” (q=2.31×10−2) 
and “Wnt/β- catenin Signalling” (q=3.07×10−2), and the functions 
“Nervous System Development and Function” (best subcategory 
q=3.71×10−11) and “Behaviour” (best subcategory q=4.69×10−5). This 
analysis was carried out using a P- value threshold of P≤.01 to define 
the target list. For comparison, and to assess the robustness of these 
findings, pathway analysis was carried out using two additional P- 
value thresholds, P≤.005 and P≤.001 (Tables S5 and S6). “Behaviour” 
was significantly enriched in both additional analyses and “Nervous 
System Development and Function” was significantly enriched when 
using a threshold of P≤.005.
2.6 | Identification of differentially 
methylated regions
To identify regions of the genome harbouring multiple (≥3) nominally 
significant DMPs (P≤.05), DMR analysis was performed. This resulted 
in the identification of 61 DMRs (Table 4). Interestingly, seven DMRs 
are located within the major histocompatibility complex (MHC; P- value 
range: 1.81×10−7–4.79×10−4), a region that has been implicated in the 
pathogenesis of schizophrenia and BD.43,51 Amongst the other DMRs 
TABLE  3 Summary of pathway analysis results
Name P- value q- value Ratioa
Canonical pathways
Dopamine- DARPP32 (Dopamine- and cAMP-
regulated phosphoprotein, Mr 32 kDa) 
feedback in cAMP signalling
4.33×10−5 2.31×10−2 47/155 (0.303)
PI3K signalling in B lymphocytes 1.21×10−4 3.07×10−2 38/122 (0.311)
Wnt/β- catenin signalling 2.28×10−4 3.07×10−2 47/165 (0.285)
Endometrial cancer signalling 2.30×10−4 3.07×10−2 20/52 (0.385)
Protein kinase A signalling 4.18×10−4 3.27×10−2 89/368 (0.242)
Name P- value range q- value range No. molecules
Molecular and cellular functions
Cell- to- cell signalling and interaction 1.72×10−15–5.15×10−3 3.71×10−11–2.61×10−1 225
Cellular assembly and organization 1.72×10−15–6.83×10−3 3.71×10−11–3.01×10−1 520
Cell death and survival 8.83×10−8–6.27×10−3 1.00×10−4–2.87×10−1 924
Cell morphology 2.67×10−6–6.57×10−3 1.20×10−3–2.97×10−1 662
Cellular development 8.43×10−6–7.42×10−3 3.30×10−3–3.19×10−1 898
Physiological system development and function
Nervous system development and function 1.72×10−15–7.42×10−3 3.71×10−11–3.19×10−1 620
Tissue morphology 1.72×10−15–7.24×10−3 3.71×10−11–3.15×10−1 582
Behaviour 3.48×10−8–6.64×10−3 4.69×10−5–2.97×10−1 283
Embryonic development 5.97×10−7–7.24×10−3 4.37×10−4–3.15×10−1 515
Organismal development 5.97×10−7–6.64×10−3 4.37×10−4–2.97×10−1 711
Diseases and disorders
Cancer 6.66×10−11–6.57×10−3 2.06×10−7–2.97×10−1 2714
Gastrointestinal disease 6.66×10−11–4.88×10−3 2.06×10−7–2.61×10−1 2042
Organismal injury and abnormalities 6.66×10−11–7.26×10−3 2.06×10−7–3.15×10−1 2717
Hepatic system disease 5.72×10−9–2.01×10−8 1.24×10−5–2.89×10−5 1185
Hereditary disorder 5.79×10−7–6.88×10−3 4.37×10−4–3.01×10−1 187
aThe ratio indicates the number of molecules associated with a particular pathway, disease or function in the target set compared to the reference set.
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TABLE  4 Differentially methylated regions (DMRs) identified in the well high- risk individuals who developed a mood disorder (IL) compared 
to the well high- risk individuals who remained well (WL), ranked by P- value
Gene symbol P- value Chr. Start coordinatea DMR size (bp) No. probes Directionb
S100A13; S100A1 4.90×10−9 1 153599240 1024 8 Up
SIAH3 1.22×10−8 13 46425082 994 6 Up
PIWIL2 2.80×10−8 8 22132877 176 6 Down
MIR146B 3.53×10−8 10 104195449 2184 5 Down
NA 1.26×10−7 10 50648574 2766 5 Down
NA 1.81×10−7 6 30094974 458 8 Up
FRK 2.19×10−7 6 116381824 177 4 Down
FOXR1 9.96×10−7 11 118842395 98 3 Down
DSN1 1.27×10−6 20 35402286 23 3 Up
MSX1 1.81×10−6 4 4864284 292 4 Up
STRA6 1.92×10−6 15 74494622 526 3 Up
FMN1 1.92×10−6 15 33360245 216 3 Down
IGF2BP1 1.92×10−6 17 47092126 292 3 Down
CRISP2 3.13×10−6 6 49680994 478 5 Down
ZFYVE28 5.75×10−6 4 2402943 2179 4 Up
NA 8.56×10−6 10 96989451 3146 4 Down
C10orf82 1.02×10−5 10 118429409 86 3 Up
LOC400794; LRRC52 1.29×10−5 1 165512892 895 4 Up
TCEAL8 1.61×10−5 X 102510031 169 3 Down
NTNG1 1.61×10−5 1 108023288 378 4 Down
NA 1.84×10−5 14 75799632 2483 3 Down
NA 1.88×10−5 6 164505176 3163 4 Down
SNX29 2.29×10−5 16 12183512 1047 3 Down
NA 2.29×10−5 1 2885051 200 4 Up
NA 3.05×10−5 8 2584143 3174 4 Down
APC2 3.53×10−5 19 1466930 180 3 Up
NA 3.53×10−5 17 76640024 2564 3 Down
NA 3.62×10−5 20 60540386 166 3 Down
RASA3 3.73×10−5 13 114829829 910 3 Down
NA 4.35×10−5 11 85392601 2386 3 Down
NA 4.55×10−5 6 32862234 199 3 Down
GABRG3 4.95×10−5 15 27215925 73 3 Down
EIF3I; C1orf91 6.10×10−5 1 32687540 77 3 Down
RPP21 7.36×10−5 6 30312957 166 3 Up
NA 8.01×10−5 10 54537213 2561 3 Down
NA 8.06×10−5 6 33866229 3244 4 Up
C6orf27 8.06×10−5 6 31733373 1607 5 Up
NA 0.000 101 16 22959736 222 3 Down
PARP9; DTX3L 0.000 101 3 122283571 128 4 Up
IQSEC1 0.000 123 3 13082461 852 3 Up
DDR1 0.000 138 6 30854046 302 3 Up
NA 0.000 139 7 75702611 2518 3 Down
UBE2U 0.000 148 1 64669387 70 3 Down
MDH2; STYXL1 0.000 160 7 75677907 398 3 Down
NA 0.000 169 5 134880228 3484 3 Up
(Continues)
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identified, a region of hypermethylation encompassing an intronic and 
exonic region of Msh Homeobox 1 (MSX1; P=1.81×10−6) is noteworthy 
in light of previous evidence for altered methylation of this gene in BD 
and schizophrenia.52
The correlation between methylation in the blood and in four 
different regions for probes contributing to the 10 most significant 
DMRs was investigated using Hannon et al.’s24 online database. These 
coefficients are presented in Table S7. All 10 DMRs contained at least 
one probe that showed a significant correlation with at least one brain 
region. Of these ten DMRs, evidence for moderate/strong correlation 
for at least one probe in at least one brain region was seen for six 
DMRs. For two DMRs, significant correlation was observed between 
methylation in the blood and all four brain regions for all probes con-
tributing to the DMR. These two DMRs are located (i) in the first exon/
intron of one Piwi-Like RNA-Mediated Gene Silencing 2 (PIWIL2) isoform 
and in the promoter region of another PIWIL2 isoform (P- value and 
correlation range: 2.32×10−9; r2=.406–.000 355; r2=.163) and (ii) in 
the promoter region of DSN1, MIS12 Kinetochore Complex Component 
(DSN1; P- value and correlation range: 3.64×10−14; r2=.622–.000 661; 
r2=.156).
3  | DISCUSSION
Accumulating evidence suggests that changes in DNA methylation 
might play a role in psychiatric illnesses, including the mood disorders 
MDD and BD.11–15,53 Due to the fact that studies carried out to date 
have involved participants who are already ill and usually medicated, it 
has not been possible to determine whether altered DNA methylation 
occurs before illness onset or as a consequence of illness progression 
or in response to treatment.
To attempt to disentangle these possibilities, we characterized 
blood- based DNA methylation in a cohort of well individuals at elevat-
ed familial risk of developing a mood disorder who were separated by 
future diagnostic status into a group that remained well and a group 
that became ill. Comparison of these two groups did not identify any 
Gene symbol P- value Chr. Start coordinatea DMR size (bp) No. probes Directionb
PRRT1 0.000 198 6 32117135 388 3 Up
NA 0.000 198 13 21900230 324 3 Up
NA 0.000 214 3 195681893 3484 3 Down
CMTM2 0.000 231 16 66613264 18 3 Up
MCTS1 0.000 256 X 119737646 562 3 Down
STC2 0.000 261 5 172749612 2495 3 Down
NA 0.000 275 7 27137009 3484 3 Up
NA 0.000 368 16 1157350 3484 3 Down
GJB6 0.000 441 13 20805265 241 3 Up
NA 0.000 441 12 120835638 166 3 Up
AIF1 0.000 479 6 31583077 1984 3 Up
TNFAIP2 0.000 519 14 103593425 173 3 Down
LSM5; AVL9 0.000 711 7 32535138 78 3 Down
NA 0.000 803 6 33129826 324 3 Down
TNFRSF11A 0.000 946 18 60052280 368 3 Up
NA 0.000 978 16 86252489 2708 3 Up
aGRCh37/hg19.
b“Up” indicates hypermethylation in the IL group; “Down” indicates hypomethylation in the IL group.
S100A13: S100 calcium-binding protein A13; S100A1: S100 calcium-binding protein A1; SIAH3: Siah E3 Ubiquitin Protein Ligase Family Member 3; 
PIWIL2: Piwi Like RNA-Mediated Gene Silencing 1; MIR146B: miRNA 146B; FRK: Fyn Related Src Family Tyrosine Kinase; FOXR1: Forkhead Box R1; 
DSN1: DSN1 Homolog, MIS12 Kinetochore Complex Component; MSX1: Msh Homeobox 1; STRA6: Stimulated By Retinoic Acid 6; FMN1: Formin 1; 
IGF2BP1: Insulin Like Growth Factor 2 MRNA Binding Protein 1; CRISP2; Cysteine-Rich Secretory Protein 2; ZFYVE28: Zinc Finger FYVE-Type Containing 
28; C10orf82: Chromosome 10 Open Reading Frame 82; LOC400794: uncharacterized LOC400794; LRRC52: Leucine Rich Repeat Containing 52; TCEAL8: 
Transcription Elongation Factor A (SII)-Like 8; NTNG1: Netrin G1; SNX29: Sorting Nexin 29; APC2: Adenomatosis Polyposis Coli 2; RASA3: RAS P21 
Protein Activator 3; GABRG3: gamma-aminobutyric acid (GABA) A receptor, gamma 3; EIF3I: Eukaryotic Translation Initiation Factor 3 Subunit I; C1orf91: 
Chromosome 1 Open Reading Frame 91; RPP21: Ribonuclease P/MRP 21kDa Subunit; C6orf27: Chromosome 6 Open Reading Frame 27; PARP9: 
Poly(ADP-Ribose) Polymerase Family Member 9; DTX3L: Deltex 3 Like, E3 Ubiquitin Ligase; IQSEC1: IQ Motif And Sec7 Domain 1; DDR1: Discoidin 
domain receptor family, member 1; UBE2U: Ubiquitin Conjugating Enzyme E2 U (Putative); MDH2: Malate Dehydrogenase 2; STYXL1: Serine/Threonine/
Tyrosine Interacting-Like 1; PRRT1: Proline-Rich Transmembrane Protein 1; CMTM2: CKLF-Like MARVEL Transmembrane Domain Containing 2; MCTS1: 
Malignant T-Cell Amplified Sequence 1; STC2: Stanniocalcin 2; GJB6: Gap junction beta-6 protein; AIF1: Allograft inflammatory factor 1; TNFAIP2: TNF 
Alpha Induced Protein 2; LSM5: LSM5 Homolog, U6 Small Nuclear RNA And MRNA Degradation Associated; AVL9: AVL9 Cell Migration Associated; 
TNFRSF11A: Tumor Necrosis Factor Receptor Superfamily Member 11a.
T A B L E  4  (Continued)
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methylation differences at individual loci that survived FDR correc-
tion; however, uncorrected P- values provided suggestive evidence for 
altered DNA methylation at a number of sites throughout the genome. 
Pathway analysis of these sites revealed FDR- significant enrichment 
for altered methylation at sites within genes involved in several neuro-
logically relevant pathways believed to contribute to the pathogenesis 
of mood disorders.
The fact that none of the site- specific differences in DNA meth-
ylation survived correction for multiple testing likely reflects both the 
limited statistical power conferred by the study of a small sample and 
issues surrounding the application of multiple testing corrections to 
epigenome- wide association studies (EWASs). The small size of our 
sample reflects the difficulties inherent in assessing premorbid differ-
ences and means that our findings must be considered exploratory and 
in need of replication. Regarding the second issue, multiple testing cor-
rection of EWASs is complicated by a lack of variability in methylation 
at many CpGs and the existence of spatial correlation between the 
methylation levels of nearby sites.16 These factors are likely to render 
many multiple testing correction procedures overly conservative.54 In 
light of these limitations, we took the decision to present and discuss 
uncorrected P- values for the single- site differential methylation anal-
ysis. As such, it is important to consider the possibility that our failure 
to identify any FDR- significant differences reflects a true lack of such 
differences and it is imperative that this caveat is borne in mind when 
considering the loci of interest discussed below.
Amongst the loci showing the most significant changes in DNA 
methylation, several sites map to genes previously implicated in 
psychiatric illness and/or with a known neurological function. One 
example is a site within the promoter region of IL1RAPL1 where we 
observed a nominally significant increase in methylation in IL individ-
uals. IL1RAPL1 encodes the X- linked interleukin- 1 receptor accessory 
protein- like 1, which is highly expressed in the brain, particularly in 
the hippocampus,48 and has been found to mediate the formation of 
excitatory synapses.55 Il1rapl1 knock- out mice show reduced corti-
cal neuron spine density, mild memory impairments, increased loco-
motor activity and reduced anxiety- like behaviours.56 Deletions and 
point mutations in IL1RAPL1 have been identified in individuals with 
mental retardation and individuals with ASD with and without mental 
retardation.44–50
Importantly, methylation at this locus has previously been shown 
to be significantly correlated between the blood and four different 
brain regions.24 The differentially methylated site is located with-
in a DNAse hypersensitivity site (DHS),57 indicating the presence of 
an open chromatin structure. As such, it is possible that the altered 
methylation observed at this site might exert an effect on IL1RAPL1 
expression.
Another nominally significant DMP rendered particularly interest-
ing by significant blood−brain correlation falls within the first intron 
of PIWIL1. Methylation at this site is significantly correlated between 
the blood and three cortical regions.24 PIWIL1 is best known for its 
role in maintaining germline integrity by repressing retrotransposon 
activity58; however, a recent study has shown that it also plays a role 
in the polarization and migration of neurons in the developing cerebral 
cortex.59 This site is located within a DHS and a chromatin immuno-
precipitation (ChIP)- identified binding site for the transcription factor 
TCF7L2,57 suggesting a potential regulatory effect.
We identified hypomethylation in IL individuals at a site located 
within TCF4. This site falls within a region of TCF4 implicated in the 
pathogenesis of schizophrenia by a recent genome- wide association 
study (GWAS).43 Moreover, a cross- disorder GWAS, which assessed 
association in individuals with schizophrenia, BD, MDD, autism spec-
trum disorders or attention deficit- hyperactivity disorder, found sug-
gestive evidence for association with a variant in TCF4, which fell just 
short of genome- wide significance.60 TCF4 encodes a basic helix- loop- 
helix transcription factor, which plays a role in multiple processes, 
including neurodevelopment.61
In order to investigate the potential biological implications of the 
observed methylation changes, we carried out pathway analysis. In 
addition to aiding in the interpretation of our results, this approach 
confers the advantage of mitigating the effects of individual false posi-
tive results, a feature that is particularly important in light of the failure 
of the single- locus results to withstand correction for multiple testing. 
Many of the significantly enriched biological pathways and functions 
that withstood correction for multiple testing pertained to neurolog-
ically relevant functions. These categories included Nervous System 
Development and Function and Behavior.
A limitation of pathway analysis of methylation data is that a sin-
gle P- value must be selected to represent each gene. IPA, by default, 
selects the most significant P- value for any probe within a given gene. 
Key to this rationale is the fact that it is possible for altered methyl-
ation at one locus to impact on gene function. As such, genes that 
contain more CpG sites are more likely to obtain a more significant 
P- value because it is more likely that their function will be altered by 
a change in methylation. Genes containing more CpG sites are also 
more likely, however, to obtain a significant P- value by chance due 
to multiple testing. The inter- relationship between these two factors 
presents an analytical challenge, as correcting for multiple testing risks 
reducing true biological signal. It is not clear how best to simultane-
ously account for both factors using currently available pathway analy-
sis methods, meaning this limitation must be taken into account when 
interpreting our findings.
In addition to considering our data at the level of individual loci, 
we carried out DMR analysis to identify regions containing multiple, 
adjacent differentially methylated loci. Several of the DMRs identified 
mapped to the MHC (n=7) or the broader extended MHC (an addi-
tional two DMRs). The most significant association in the Psychiatric 
Genomics Consortium’s latest GWAS of schizophrenia43 was within 
the MHC and a GWAS involving a combined schizophrenia and BD 
case group also identified association with this region.51 These genetic 
findings are in keeping with evidence from clinical observations, and 
animal and cellular models that implicate perturbed immune function 
in the pathogenesis of mood disorders.62,63
Among the other DMRs identified, a 272- bp region of hyper-
methylation spanning an intronic and exonic region at the 5ʹ end of 
MSX1 is of particular interest. In a recent study of DNA methylation 
at sites within γ- aminobutyric acid- related genes in the post- mortem 
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hippocampus of individuals with schizophrenia or BD, the majority 
of significant DMPs and DMRs were found to map to MSX1.52 MSX1 
encodes a transcription factor that is involved in regulating central 
nervous system development, including the differentiation of midbrain 
dopaminergic neurons.64,65 Hannon et al.24 identified a significant 
positive correlation between methylation in the blood and the STG for 
three of the four probes that form this DMR.
A region of hypomethylation found to affect the first exon/intron 
of one PIWIL2 isoform and the promoter region of another PIWIL2 
isoform was of particular interest given the consistently significant 
positive correlation between methylation in blood and all four brain 
regions observed by Hannon et al.24 for the five loci involved in this 
DMR. Taken together with our finding of hypomethylation at the 
PIWIL1 locus, this result suggests that further investigation of the role 
of the PIWI pathway in neuronal function and psychiatric illness may 
be warranted.
In common with pathway analysis, a key advantage to DMR anal-
ysis is that it serves to reduce the influence of individual false positive 
results; however, there are some important limitations to DMR anal-
ysis that must be considered. The ability to detect DMRs is affect-
ed by the representation of a given genomic region on the Infinium 
HumanMethylation450 BeadChip. Although the method we utilized 
to detect DMRs does attempt to account for this, it is clear that DMPs 
that are located in regions that are otherwise probe deserts will never 
be detected through DMR analysis. A pertinent example is the TCF4 
probe cg15171911: although this probe showed nominally signifi-
cant differential methylation in our single- locus analysis, it could not 
contribute to a DMR as the nearest site represented in our dataset is 
located ~79 kb away. As such, the results of DMP and DMR analyses 
should be considered complementary. A second issue surrounding the 
detection of DMRs is that decisions must be made regarding several 
parameters, such as the number of adjacent probes required to form a 
DMR, the significance level that must be attained by individual probes 
contributing to the DMR, and the width of the window in which to 
search for DMRs. At this time, there is no standard definition of a 
DMR, limiting the ability to compare DMR results between studies.
Our analysis concerns a broad diagnostic category, termed mood 
disorder, which comprises both MDD and BD. The majority of individu-
als in the group who later developed a mood disorder were diagnosed 
with MDD; however, it is likely that some of these individuals will lat-
er develop BD. A longitudinal study of the offspring of parents with 
BD has previously shown that the majority of those who eventually 
developed BD received a first diagnosis of MDD.66 The mean period 
between the onset of MDD and the appearance of the first (hypo)
manic episode was 4.9 y. Follow- up of the individuals involved in the 
BFS is ongoing, thus permitting future studies to address questions 
relating to more specific diagnostic categories, once the diagnostic 
statuses of the participants have stabilized.
We profiled DNA methylation in whole blood, a heterogeneous 
tissue comprising multiple cell types. As each blood- cell subtype is 
characterized by a distinct methylation profile, it is possible for vari-
ation in blood composition to confound studies of whole- blood DNA 
methylation.36,67 As cell count data were not available for our samples, 
we estimated the proportions of six blood cell subtypes and compared 
these proportions between groups. We identified a significant differ-
ence in the proportion of CD4+ T cells. Since estimates of blood cell 
proportions are made with an associated error, it is unclear how they 
should be used to control for differences in blood cell composition. 
Recently, Jaffe and Irizarry (2014) recommended using SVA to con-
trol for cell- type composition effects when levels of confounding are 
low. We therefore utilized SVA to minimize confounding by cell com-
position variation. Additionally, for two DMPs of particular interest, 
TCF4 and IL1RAPL1, we demonstrated that there was no relationship 
between methylation level and the estimated proportion of CD4+ T 
cells.
In addition to accounting for the effects of variation in cellular 
composition on DNA methylation, SVA also controls for any other 
unmeasured/unmodelled variables that exert a systematic effect on 
DNA methylation. As such, we have controlled for the confounding 
effects of variables such as cigarette smoking, which alter methyla-
tion.68 Since SVA operates in a hypothesis- free manner, it negates the 
need to decide on the most appropriate measure of a variable to fit 
as a covariate. This is particularly advantageous when considering a 
complex behaviour, such as smoking, which can be described in many 
ways, including multiple aspects of current smoking behaviour, former 
smoking behaviour and exposure to the smoke of others.
A perennial issue in the study of psychiatric disorders is the dif-
ficulty in accessing the most physiologically relevant tissue (i.e. the 
brain). This prompts a key and unresolved question regarding the util-
ity of studying DNA methylation in a peripheral tissue, such as the 
blood. Clearly, the importance of the blood−brain correlation depends 
on whether peripheral methylation differences are being assessed for 
their potential to act as a biomarker of illness (i.e. a signature of illness) 
or as a key to understanding the underlying pathophysiology of the 
condition (i.e. a mirror of methylation differences in the brain).69 Clearly, 
covariation between blood and brain methylation is only necessary in 
the latter case. A recent study has found within- individual correlation 
between DNA methylation in the blood and the brain to be low for 
the majority of sites measured by the Infinium HumanMethylation450 
BeadChip; however, there are some exceptions.24 Examination of 
blood−brain correlation coefficients24 for the loci of interest identified 
here suggests the possibility of a mixture of “signature” and “mirror” 
effects. The enrichment for several neurologically relevant terms in 
our pathway analysis results suggests, however, that, despite exten-
sive between- tissue variation, when considered together methylation 
differences measured in the blood might be capable of highlighting 
potential pathogenic mechanisms.
4  | CONCLUSIONS
Here we report the first genome- wide characterization of DNA 
methylation in individuals prior to the onset of mood disorders and, 
through the identification of affected genes and pathways, elucidate 
potential biological mechanisms through which altered methylation 
might confer risk. Importantly, the IL individuals did not score higher 
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than the WL group on measures of depressive or manic symptoms 
at the time that their blood sample was obtained. This indicates that 
the DNA methylation changes observed do not simply reflect the 
presence of an undiagnosed mood disorder at the time of the blood 
draw. As we compared two groups of individuals who were both at 
an elevated familial risk of developing a mood disorder, the changes in 
DNA methylation we observed may reflect premorbid dysregulation 
in the group who later became ill or protective changes in the group 
who remained well. Future studies profiling DNA methylation at a 
second time point may aid in disentangling these mechanisms. The 
current study was under- powered to address the question of whether 
premorbid DNA methylation differs between individuals who develop 
MDD and those who develop BD; however, this would be an interest-
ing question to address in the future. Our findings add to a recent 
imaging study involving an overlapping set of individuals from the 
BFS cohort, which identified increased activity in the insula cortex, 
a brain region involved in emotional processing, during a sentence 
completion task in the individuals who developed MDD.27 Together, 
these studies highlight the value of longitudinal cohort studies for 
addressing questions of causality, which typically plague case–con-
trol studies.
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